The United States have doubled their financial investment in almost a billion dollars in total, to support the development of a potential vaccine against the COVID-19 developed by the american society Moderna, which between Monday, in the latest phase of its clinical trial.
The u.s. government is committed to bring in up to $ 472 million additional 483 million already announced, announced on Sunday Moderna in a press release.
This extension is justified according to the biotech company because it has decided “to conduct a phase 3 clinical trial significantly more extensive” than initially expected.
His experimental vaccine, which has raised antibodies against the coronavirus among all participants, the number of 45, in the first phase of the trial, will be tested from Monday, about 30 000 people: half of them will receive a dose of 100 micrograms, the other a placebo.
The United States, the country most grief-stricken in the world, with more than 146,000 deaths, and the number of new cases daily explodes, have announced in recent months of massive investment aimed to immunize Americans from the beginning of the next year.
On Wednesday, the alliance German-american Biontech/Pfizer had declared that the u.s. government would pay him 1,95 billion dollars to ensure that 100 million doses of any vaccine.
While the race for the vaccine is raging between several laboratories throughout the world, one of Moderna is in the head of the pack by entering in the final phase of clinical trials determines whether it is effective and safe.
The trial is being conducted in collaboration with the u.s. health authorities, recalls the company, which reaffirms to be able to provide about 500 million doses per year, and potentially up to a billion, as of 2021.
The chinese Sinovac also announced on 6 July that the three-phase development of its vaccine would commence “this month”, in collaboration with the brazilian Butantan.
Other projects have shown encouraging results, including a british developed by the university of Oxford in partnership with the laboratoire AstraZeneca, and another, chinese, conducted by researchers from several organizations, including the School of military medical sciences, funded by the group of biotechnology listed in Hong Kong, CanSino Biologics.
In all, nearly 200 candidate vaccines are developed, 23 of which are in clinical phase, it is tested in humans.